CPB2

Summary

Gene Symbol: CPB2
Description: carboxypeptidase B2 (plasma)
Alias: CPU, PCPB, TAFI, carboxypeptidase B-like protein, carboxypeptidase B2, carboxypeptidase B2 (plasma, carboxypeptidase U), carboxypeptidase U, plasma carboxypeptidase B, thrombin-activable fibrinolysis inhibitor, thrombin-activatable fibrinolysis inhibitor
Species: human

Top Publications

  1. ncbi Influence of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 gene polymorphisms on tissue-type plasminogen activator-induced recanalization in ischemic stroke patients
    I Fernandez-Cadenas
    Neurovascular Research Laboratory, Neurovascular Unit, Department of Neurology of Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, Vall d Hebron University Hospital, Barcelona, Spain
    J Thromb Haemost 5:1862-8. 2007
  2. ncbi Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1
    Mirjam E Meltzer
    Department of Clinical Chemistry and Hematology, University Medical Center Utrecht, Utrecht, The Netherlands
    Blood 116:113-21. 2010
  3. ncbi Thrombin-activable fibrinolysis inhibitor (TAFI) zymogen is an active carboxypeptidase
    Zuzana Valnickova
    Center for Insoluble Protein Structure at the Department of Molecular Biology, Science Park, University of Aarhus, Gustav Wieds Vej 10C, 8000 Aarhus C, Denmark
    J Biol Chem 282:3066-76. 2007
  4. ncbi The crystal structure of thrombin-activable fibrinolysis inhibitor (TAFI) provides the structural basis for its intrinsic activity and the short half-life of TAFIa
    Kanchan Anand
    Sanofi Aventis Pharma Deutschland GmbH, Industriepark Hochst, 65926 Frankfurt am Main, Germany
    J Biol Chem 283:29416-23. 2008
  5. ncbi Increased plasma thrombin-activatable fibrinolysis inhibitor levels in normotensive type 2 diabetic patients with microalbuminuria
    Yutaka Yano
    Third Department of Internal Medicine, Mie University School of Medicine, Tsu, Mie 514 8507, Japan
    J Clin Endocrinol Metab 88:736-41. 2003
  6. ncbi Structure of activated thrombin-activatable fibrinolysis inhibitor, a molecular link between coagulation and fibrinolysis
    Laura Sanglas
    Institut de Biotecnologia i de Biomedicina and Departament de Bioquímica i Biologia Molecular Facultat de Ciències, Universitat Autonoma de Barcelona, E 08193 Bellaterra, Spain
    Mol Cell 31:598-606. 2008
  7. ncbi Increased circulating levels of thrombin-activatable fibrinolysis inhibitor in lung cancer patients
    Osamu Hataji
    Third Department of Internal Medicine, Respiratory Division, Mie University School of Medicine, Edobashi 2 174, Tsu City, Mie 514 8507, Japan
    Am J Hematol 76:214-9. 2004
  8. ncbi Inactivation of C3a and C5a octapeptides by carboxypeptidase R and carboxypeptidase N
    William D Campbell
    Choju Medical Institute, Fukushimura Hospital, Toyohashi, Aichi, Japan
    Microbiol Immunol 46:131-4. 2002
  9. ncbi Metabolic syndrome accompanied by hypercholesterolemia is strongly associated with proinflammatory state and impairment of fibrinolysis in patients with type 2 diabetes: synergistic effects of plasminogen activator inhibitor-1 and thrombin-activatable fib
    Yoshimasa Aso
    Department of Internal Medicine, Koshigaya Hospital, Dokkyo University School of Medicine, 2 1 50 Minami Koshigaya, Koshiagya, Saitama 343 8555, Japan
    Diabetes Care 28:2211-6. 2005
  10. ncbi Post-translational modifications of human thrombin-activatable fibrinolysis inhibitor (TAFI): evidence for a large shift in the isoelectric point and reduced solubility upon activation
    Zuzana Valnickova
    Center for Insoluble Protein Structure inSPIN at the Department of Molecular Biology, Science Park, University of Aarhus, Gustav Wied s Vej 10C, 8000 Aarhus C, Denmark
    Biochemistry 45:1525-35. 2006

Research Grants

  1. Factor Xl in Vascular Thrombosis
    David Gailani; Fiscal Year: 2010
  2. Factor Xl in Vascular Thrombosis
    David Gailani; Fiscal Year: 2007
  3. Carboxypeptidases in Thrombosis and Inflammation
    Laszlo Bajzar; Fiscal Year: 2007
  4. STRUCTURAL STUDIES OF BLOOD CLOTTING PROTEINS
    JOHN WEISEL; Fiscal Year: 2004
  5. CLASSICAL AND ALTERNATIVE PATHWAYS OF FIBRINOLYSIS
    Edward Plow; Fiscal Year: 2005
  6. CLASSICAL AND ALTERNATIVE PATHWAYS OF FIBRINOLYSIS
    EDWARD FRANKLIN PLOW; Fiscal Year: 2010
  7. CLASSICAL AND ALTERNATIVE PATHWAYS OF FIBRINOLYSIS
    Edward Plow; Fiscal Year: 2007
  8. Clotting genetic variant, hormones and venous thrombosis
    Nicholas Smith; Fiscal Year: 2007
  9. EPCR, TAFI as Regulators of PMN/Endothelial Interaction
    Florea Lupu; Fiscal Year: 2009
  10. MECHANISMS OF MICROVASULAR THROMBOSIS IN BABOONS
    Fletcher Taylor; Fiscal Year: 2002

Detail Information

Publications183 found, 100 shown here

  1. ncbi Influence of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 gene polymorphisms on tissue-type plasminogen activator-induced recanalization in ischemic stroke patients
    I Fernandez-Cadenas
    Neurovascular Research Laboratory, Neurovascular Unit, Department of Neurology of Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, Vall d Hebron University Hospital, Barcelona, Spain
    J Thromb Haemost 5:1862-8. 2007
    ..Thrombin-activatable fibrinolysis inhibitor (TAFI) and plasminogen activator inhibitor-1 (PAI-1) are fibrinolysis inhibitors...
  2. ncbi Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1
    Mirjam E Meltzer
    Department of Clinical Chemistry and Hematology, University Medical Center Utrecht, Utrecht, The Netherlands
    Blood 116:113-21. 2010
    ..levels were the main determinants of CLT, followed by plasminogen, thrombin-activatable fibrinolysis inhibitor (TAFI), prothrombin, and alpha2-antiplasmin. Fibrinogen, factor VII, X, and XI contributed minimally...
  3. ncbi Thrombin-activable fibrinolysis inhibitor (TAFI) zymogen is an active carboxypeptidase
    Zuzana Valnickova
    Center for Insoluble Protein Structure at the Department of Molecular Biology, Science Park, University of Aarhus, Gustav Wieds Vej 10C, 8000 Aarhus C, Denmark
    J Biol Chem 282:3066-76. 2007
    Thrombin-activable fibrinolysis inhibitor (TAFI) is a carboxypeptidase found in human plasma, presumably as an inactive zymogen...
  4. ncbi The crystal structure of thrombin-activable fibrinolysis inhibitor (TAFI) provides the structural basis for its intrinsic activity and the short half-life of TAFIa
    Kanchan Anand
    Sanofi Aventis Pharma Deutschland GmbH, Industriepark Hochst, 65926 Frankfurt am Main, Germany
    J Biol Chem 283:29416-23. 2008
    ..In accordance with its in vitro antifibrinolytic activity, animal studies have reported that inhibition of mature TAFI aids in the prevention of thrombosis...
  5. ncbi Increased plasma thrombin-activatable fibrinolysis inhibitor levels in normotensive type 2 diabetic patients with microalbuminuria
    Yutaka Yano
    Third Department of Internal Medicine, Mie University School of Medicine, Tsu, Mie 514 8507, Japan
    J Clin Endocrinol Metab 88:736-41. 2003
    ..Recently, a new potent inhibitor of fibrinolysis, the thrombin-activatable fibrinolysis inhibitor (TAFI), has been isolated from human plasma...
  6. ncbi Structure of activated thrombin-activatable fibrinolysis inhibitor, a molecular link between coagulation and fibrinolysis
    Laura Sanglas
    Institut de Biotecnologia i de Biomedicina and Departament de Bioquímica i Biologia Molecular Facultat de Ciències, Universitat Autonoma de Barcelona, E 08193 Bellaterra, Spain
    Mol Cell 31:598-606. 2008
    Thrombin-activatable fibrinolysis inhibitor (TAFI) is a metallocarboxypeptidase (MCP) that links blood coagulation and fibrinolysis. TAFI hampers fibrin-clot lysis and is a pharmacological target for the treatment of thrombotic conditions...
  7. ncbi Increased circulating levels of thrombin-activatable fibrinolysis inhibitor in lung cancer patients
    Osamu Hataji
    Third Department of Internal Medicine, Respiratory Division, Mie University School of Medicine, Edobashi 2 174, Tsu City, Mie 514 8507, Japan
    Am J Hematol 76:214-9. 2004
    ..This study suggests that thrombin-activatable fibrinolysis inhibitor, in part secreted from lung cancer cells, may play a role in the pathogenesis of thrombotic disorders in lung cancer patients...
  8. ncbi Inactivation of C3a and C5a octapeptides by carboxypeptidase R and carboxypeptidase N
    William D Campbell
    Choju Medical Institute, Fukushimura Hospital, Toyohashi, Aichi, Japan
    Microbiol Immunol 46:131-4. 2002
    ..also known as thrombin-activatable fibrinolysis inhibitor (TAFI), precursor of carboxypeptidase U and plasma carboxypeptidase B is present in plasma and following activation by thrombin/thrombomodulin and/or plasmin can remove ..
  9. ncbi Metabolic syndrome accompanied by hypercholesterolemia is strongly associated with proinflammatory state and impairment of fibrinolysis in patients with type 2 diabetes: synergistic effects of plasminogen activator inhibitor-1 and thrombin-activatable fib
    Yoshimasa Aso
    Department of Internal Medicine, Koshigaya Hospital, Dokkyo University School of Medicine, 2 1 50 Minami Koshigaya, Koshiagya, Saitama 343 8555, Japan
    Diabetes Care 28:2211-6. 2005
    To determine whether plasma concentrations of thrombin-activatable fibrinolysis inhibitor (TAFI) in patients with type 2 diabetes were associated with components of metabolic syndrome (MS), including high-sensitivity C-reactive protein (..
  10. ncbi Post-translational modifications of human thrombin-activatable fibrinolysis inhibitor (TAFI): evidence for a large shift in the isoelectric point and reduced solubility upon activation
    Zuzana Valnickova
    Center for Insoluble Protein Structure inSPIN at the Department of Molecular Biology, Science Park, University of Aarhus, Gustav Wied s Vej 10C, 8000 Aarhus C, Denmark
    Biochemistry 45:1525-35. 2006
    Thrombin-activable fibrinolysis inhibitor (TAFI) is distinct from pancreatic procarboxypeptidase B in several ways. The enzymatic activity of TAFIa is unstable and decays with a half-life of a few minutes...
  11. ncbi Limited mutagenesis increases the stability of human carboxypeptidase U (TAFIa) and demonstrates the importance of CPU stability over proCPU concentration in down-regulating fibrinolysis
    Wolfgang Knecht
    AstraZeneca R and D Molndal, Molndal, Sweden
    FEBS J 273:778-92. 2006
    Procarboxypeptidase U [proCPU, thrombin-activatable fibrinolysis inhibitor (TAFI), EC 3.4.17.20] belongs to the metallocarboxypeptidase family and is a zymogen found in human plasma...
  12. ncbi A functional single nucleotide polymorphism in the thrombin-activatable fibrinolysis inhibitor (TAFI) gene associates with outcome of meningococcal disease
    J A Kremer Hovinga
    Laboratory for Experimental Internal Medicine, Academic Medical Center, Amsterdam, The Netherlands
    J Thromb Haemost 2:54-7. 2004
    ..Recently, TAFI (thrombin-activatable fibrinolysis inhibitor) was identified as a link between coagulation and fibrinolysis, as ..
  13. ncbi Inactivation of active thrombin-activable fibrinolysis inhibitor takes place by a process that involves conformational instability rather than proteolytic cleavage
    P F Marx
    Thrombosis and Haemostasis Laboratory, Department of Haematology, University Medical Center, P O Box 85500, 3508 GA Utrecht, The Netherlands
    J Biol Chem 275:12410-5. 2000
    Thrombin-activable fibrinolysis inhibitor (TAFI) is present in the circulation as an inactive zymogen...
  14. ncbi TAFI gene haplotypes, TAFI plasma levels and future risk of coronary heart disease: the PRIME Study
    P E Morange
    INSERM U626, Hematology Laboratory, Faculty of Medicine, CHU Timone, Marseille, France
    J Thromb Haemost 3:1503-10. 2005
    To evaluate the association of thrombin-activatable fibrinolysis inhibitor (TAFI) gene polymorphisms with the risk of coronary heart disease (CHD) and with TAFI levels measured by a newly developed enzyme-linked immunosorbent assay (ELISA)..
  15. ncbi Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase B from human plasma
    D L Eaton
    Department of Cardiovascular Research, Genentech, Inc, South San Francisco, California 94080
    J Biol Chem 266:21833-8. 1991
    ..We propose that the Mr 60,000 plasminogen-binding protein isolated here is a novel human plasma carboxypeptidase B and that it be designated pCPB.
  16. ncbi TAFIa, PAI-1 and alpha-antiplasmin: complementary roles in regulating lysis of thrombi and plasma clots
    N J Mutch
    Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK
    J Thromb Haemost 5:812-7. 2007
    ..b>Thrombin activatable fibrinolysis inhibitor (TAFI), a plasma procarboxypeptidase activated by thrombin-thrombomodulin to form TAFIa, also ..
  17. ncbi Activated human plasma carboxypeptidase B is retained in the blood by binding to alpha2-macroglobulin and pregnancy zone protein
    Z Valnickova
    Duke University Medical Center, Department of Pathology, Durham, North Carolina 27710, USA
    J Biol Chem 271:12937-43. 1996
    ..The specific binding of plasma CPB to alpha-macroglobulins suggest that these proteins may function as a "shuttle" in vivo to modulate the clearance of plasma CPB from the circulatory system...
  18. ncbi TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex
    L Bajzar
    Department of Biochemistry, Queen s University, Kingston, Ontario K7L 3N6, Canada
    J Biol Chem 271:16603-8. 1996
    b>TAFI (thrombin-activatable fibrinolysis inhibitor) is a recently discovered plasma protein that can be activated by thrombin-catalyzed proteolysis to a carboxypeptidase B-like enzyme that inhibits fibrinolysis...
  19. ncbi Thrombin activatable fibrinolysis inhibitor, a potential regulator of vascular inflammation
    Timothy Myles
    Division of Hematology, Department of Medicine, Stanford University School of Medicine, California 94305, USA
    J Biol Chem 278:51059-67. 2003
    The latent plasma carboxypeptidase thrombin-activable fibrinolysis inhibitor (TAFI) is activated by thrombin/thrombomodulin on the endothelial cell surface, and functions in dampening fibrinolysis...
  20. ncbi Comparative evaluation of stable TAFIa variants: importance of alpha-helix 9 and beta-sheet 11 for TAFIa (in)stability
    E Ceresa
    Laboratory for Pharmaceutical Biology, Faculty of Pharmaceutical Sciences, Katholieke Universiteit Leuven, Leuven, Belgium
    J Thromb Haemost 5:2105-12. 2007
    Activated thrombin activatable fibrinolysis inhibitor (TAFIa) plays a pivotal role in fibrinolysis. TAFIa activity is regulated by a temperature-dependent instability...
  21. ncbi Crystal structures of TAFI elucidate the inactivation mechanism of activated TAFI: a novel mechanism for enzyme autoregulation
    Pauline F Marx
    Department of Experimental Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Blood 112:2803-9. 2008
    Thrombin-activatable fibrinolysis inhibitor (TAFI) is a pro-metallocarboxypeptidase that can be proteolytically activated (TAFIa)...
  22. ncbi Identification and characterization of two thrombin-activatable fibrinolysis inhibitor isoforms
    L Zhao
    Department of Cardiovascular Research, Berlex Biosciences, Richmond, California 94804, USA
    Thromb Haemost 80:949-55. 1998
    Thrombin-activatable fibrinolysis inhibitor (TAFI) is synthesized by the liver and is thought to circulate in plasma as a plasminogen-bound zymogen...
  23. ncbi Biochemical importance of glycosylation in thrombin activatable fibrinolysis inhibitor
    Karlien Buelens
    Laboratory for Pharmaceutical Biology, Faculty of Pharmaceutical Sciences, Katholieke Universiteit Leuven, Campus Gasthuisberg, O and N2, PB 824, Herestraat 49, B 3000 Leuven, Belgium
    Circ Res 102:295-301. 2008
    Activated Thrombin Activatable Fibrinolysis Inhibitor (TAFIa) exerts an antifibrinolytic effect by removing C-terminal lysines from partially degraded fibrin...
  24. ncbi Factor XI dependent and independent activation of thrombin activatable fibrinolysis inhibitor (TAFI) in plasma associated with clot formation
    B N Bouma
    Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA, USA
    Thromb Haemost 82:1703-8. 1999
    b>Thrombin Activatable Fibrinolysis Inhibitor (TAFI) also known as plasma procarboxypeptidase B is activated by relatively high concentrations of thrombin in a reaction stimulated by thrombomodulin...
  25. ncbi Blood coagulation and fibrinolysis in patients with Cushing's syndrome: increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels
    C Erem
    Karadeniz Technical University Faculty of Medicine, Department of Internal Medicine, Division of Endocrinology and Metabolism, Trabzon, Turkey
    J Endocrinol Invest 32:169-74. 2009
    ..To our knowledge, plasma tissue factor pathway inhibitor (TFPI) and thrombin-activatable fibrinolysis inhibitor (TAFI) levels in these patients have not been investigated...
  26. ncbi Role of isoleucine residues 182 and 183 in thrombin-activatable fibrinolysis inhibitor
    P F Marx
    Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    J Thromb Haemost 3:1293-300. 2005
    Thrombin-activatable fibrinolysis inhibitor (TAFI) is a procarboxypeptidase that, once activated, can attenuate fibrinolysis. The active form, TAFIa, is a labile enzyme, with a half-life of a few minutes at 37 degrees C...
  27. ncbi Effects of recombinant activated factor VII on thrombin-mediated feedback activation of coagulation
    Taro Taketomi
    Division of Cardiothoracic Anesthesia, Department of Anesthesiology, Emory University School of Medicine, Atlanta, Georgia, USA
    Blood Coagul Fibrinolysis 19:135-41. 2008
    ..Sustained thrombin generation also activates thrombin-activatable fibrinolysis inhibitor (TAFI), which stabilizes fibrin clot against fibrinolysis...
  28. ncbi Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis: a randomized cross-over study of two low-dose oral contraceptives
    J C Meijers
    Department of Haematology, University Medical Center Utrecht, The Netherlands
    Thromb Haemost 84:9-14. 2000
    ..These OC-induced changes were not different between the two contraceptive pills. TAFI (thrombin-activatable fibrinolysis inhibitor) levels increased on levonorgestrel, and even further increased on ..
  29. ncbi Total thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and pro-TAFI in patients with haemophilia A
    J Antovic
    Coagulation Research, Department of Surgical Sciences, Karolinska Institutet, Karolinska Hospital, Stockholm, Sweden
    Haemophilia 7:557-60. 2001
    ..It can be catalysed into its active form, TAFI (TAFIa, carboxypeptidase U or B) by a complex of thrombin/thrombomodulin...
  30. ncbi Contact activation prolongs clot lysis time in human plasma: role of thrombin-activatable fibrinolysis inhibitor and Factor XIII
    Vance G Nielsen
    Department of Anesthesiology, University of Alabama at Birmingham, 619 South 19th Street, Birmingham, AL 35249 6810, USA
    J Heart Lung Transplant 25:1247-52. 2006
    ..However, contact activation and Factor XI have enhanced thrombin-activatable fibrinolysis inhibitor (TAFI) activation and decreased fibrinolysis, and Factor XIII (FXIII) also delays fibrinolysis via alpha(2)-anti-plasmin ..
  31. ncbi [Thrombin activatable fibrinolysis inhibitor (TAFI) in allergic asthma patients]
    Izabela Kemona-Chetnik
    Klinika Alergologii i Chorob Wewnetrznych, Akademii Medycznej w Białymstoku
    Przegl Lek 63:1281-5. 2006
    Increased thrombin generation occurs in the airways of asthmatic patients. Thrombin activatable fibrinolysis inhibitor (TAFI) is a carboxypeptidase B-like proenzyme which after activation by a thrombin-thrombomodulin complex inhibits ..
  32. ncbi Enhancement of fibrinolysis by EF6265 [(S)-7-amino-2-[[[(R)-2-methyl-1-(3-phenylpropanoylamino)propyl]hydroxyphosphinoyl] methyl]heptanoic acid], a specific inhibitor of plasma carboxypeptidase B
    Kokichi Suzuki
    Pharmaceutical Research Center, Meiji Seika Kaisha, Ltd, Yokohama, Japan
    J Pharmacol Exp Ther 309:607-15. 2004
    Plasma procarboxypeptidase B, also known as thrombin-activatable fibrinolysis inhibitor (TAFI), is converted by thrombin into the active enzyme, carboxypeptidase B (CPB)/activated TAFI...
  33. ncbi Tissue factor-expressing monocytes inhibit fibrinolysis through a TAFI-mediated mechanism, and make clots resistant to heparins
    Fabrizio Semeraro
    Department of Biomedical Sciences and Human Oncology, Section of General and Experimental Pathology, University of Bari, Bari, Italy
    Haematologica 94:819-26. 2009
    Thrombin is the main activator of the fibrinolysis inhibitor TAFI (thrombin activatable fibrinolysis inhibitor) and heightened clotting activation is believed to impair fibrinolysis through the increase of thrombin activatable ..
  34. ncbi A comprehensive study on hemostasis in CAPD patients treated with erythropoietin
    Jolanta Malyszko
    Department of Nephrology and Internal Medicine, Bialystok University School of Medicine, Bialystok, Poland
    Perit Dial Int 22:582-92. 2002
    ..b>Thrombin activatable fibrinolysis inhibitor (TAFI) is a key protein linking coagulation and fibrinolysis...
  35. ncbi Arthritis is linked to local and systemic activation of coagulation and fibrinolysis pathways
    A K So
    Service of Rheumatology, University Hospital of Lausanne, Lausanne, Switzerland
    J Thromb Haemost 1:2510-5. 2003
    ..Objective: To determine the extent of activation of the coagulation and fibrinolytic pathways in different joint diseases in humans and to ascertain the factors that may influence fibrin deposition within the joint...
  36. ncbi [The TAFI system. The new role of fibrinolysis]
    C E Dempfle
    Universitatsklinikum Mannheim, I Medizinische Klinik, Theodor Kutzer Ufer 1 3, 68167 Mannheim
    Hamostaseologie 27:278-81. 2007
    ..The thrombin-activated fibrinolysis inhibitor (TAFI) is an important regulator of fibrinolysis...
  37. ncbi Plasma thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 levels in inflammatory bowel disease
    Ioannis E Koutroubakis
    Department of Gastroenterology, University Hospital Heraklion, Heraklion, Crete, Greece
    Eur J Gastroenterol Hepatol 20:912-6. 2008
    ..As plasminogen activator inhibitor-1 (PAI-1) and thrombin-activatable fibrinolysis inhibitor (TAFI) are inhibitors of fibrinolysis, we studied TAFI as well as PAI-1 plasma levels in IBD patients compared with ..
  38. ncbi Regulation of fibrinolysis in plasma by TAFI and protein C is dependent on the concentration of thrombomodulin
    L O Mosnier
    Dept of Haematology, University Medical Center, Utrecht, The Netherlands
    Thromb Haemost 85:5-11. 2001
    b>Thrombin activatable fibrinolysis inhibitor (TAFI) is a carboxypeptidase B-like proenzyme, that after activation down regulates fibrinolysis. TAFI is activated by thrombin in the presence of the cofactor thrombomodulin (TM)...
  39. ncbi Generation and characterization of a highly stable form of activated thrombin-activable fibrinolysis inhibitor
    Pauline F Marx
    Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, 1100 DD Amsterdam, The Netherlands
    J Biol Chem 279:6620-8. 2004
    ..TAFIa is a labile enzyme that can be inactivated by conformational instability or proteolysis. TAFI is approximately 40% identical to pancreatic carboxypeptidase B (CPB)...
  40. ncbi Bispecific targeting of thrombin activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 by a heterodimer diabody
    J Develter
    Laboratory for Pharmaceutical Biology, Faculty of Pharmaceutical Sciences, Katholieke Universiteit Leuven, Leuven, Belgium
    J Thromb Haemost 6:1884-91. 2008
    b>Thrombin activatable fibrinolysis inhibitor (TAFI) and plasminogen activator inhibitor-1 (PAI-1) play important roles in fibrinolysis. Both reduce plasmin generation, but they exert their antifibrinolytic effects via different mechanisms...
  41. ncbi Increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels in patients with primary hyperparathyroidism
    Cihangir Erem
    Division of Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, Karadeniz Technical University, 61080 Trabzon, Turkey
    Eur J Endocrinol 160:863-8. 2009
    ..To our knowledge, plasma tissue factor pathway inhibitor (TFPI) and thrombin-activatable fibrinolysis inhibitor (TAFI) levels in these patints have not been investigated...
  42. ncbi Risk of ischemic stroke associated with functional thrombin-activatable fibrinolysis inhibitor plasma levels
    A Santamaria
    Department of Hematology, Hospital de la Santa Creu i Sant Pau, C Sant Antoni Ma Claret, 167, 08025 Barcelona, Spain
    Stroke 34:2387-91. 2003
    Recently, a novel procarboxypeptidase B-like proenzyme, called thrombin-activatable fibrinolysis inhibitor (TAFI), has been described. It plays an important role in the delicate balance between coagulation and fibrinolysis...
  43. ncbi Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U)
    B N Bouma
    Thrombosis and Haemostasis Laboratory, Department of Haematology, University Medical Center, Utrecht, The Netherlands
    J Thromb Haemost 1:1566-74. 2003
    ..was described, which downregulated fibrinolysis after it was activated by thrombin, and was therefore named TAFI (thrombin-activatable fibrinolysis inhibitor; EC 3.4.17.20)...
  44. ncbi Characterization of thrombin activatable fibrinolysis inhibitor in normal and acquired haemostatic dysfunction
    Cheng Hock Toh
    Roald Dahl Haemostasis and Thrombosis Centre, Royal Liverpool University Hospital, Liverpool, UK
    Blood Coagul Fibrinolysis 14:S69-71. 2003
    b>Thrombin activatable fibrinolysis inhibitor (TAFI) is a carboxypeptidase B-like proenzyme, which is synthesized in the liver and circulates in the blood at a concentration of about 275 nmol/l...
  45. ncbi Thrombin activatable fibrinolysis inhibitor: not just an inhibitor of fibrinolysis
    Laszlo Bajzar
    McMaster University, Hamilton, Ontario, Canada
    Crit Care Med 32:S320-4. 2004
    To review the activation of thrombin activatable fibrinolysis inhibitor (TAFI) and activity of activated TAFI (TAFIa) as it relates to the regulation of both fibrinolytic and proinflammatory substances.
  46. ncbi Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor in patients with hyperthyroidism
    Cihangir Erem
    Division of Endocrinology and Metabolism, Department of Internal Medicine, Karadeniz Technical University Faculty of Medicine, K T Ü Tıp Fakültesi, Ic Hastaliklari Anabilim Dali, 61080 Trabzon, Turkey
    Endocrine 36:473-8. 2009
    ..The levels of plasma thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and tissue factor pathway inhibitor (TFPI) have been very rarely investigated in patients with ..
  47. ncbi The profibrinolytic effect of plasma thrombomodulin in factor XI deficiency and its implications in hemostasis
    L Dai
    The Haemophilia Reference Center, Center for Haemostasis and Thrombosis, St Thomas Hospital, London, UK
    J Thromb Haemost 2:2200-4. 2004
    ..tendency in factor (F)XI deficiency may result from premature clot lysis due to insufficient thrombin activatable fibrinolysis inhibitor (TAFI) activation...
  48. ncbi Platelet factor 4 inhibits thrombomodulin-dependent activation of thrombin-activatable fibrinolysis inhibitor (TAFI) by thrombin
    Laurent O Mosnier
    Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California 92037, USA
    J Biol Chem 286:502-10. 2011
    ..TM) is a cofactor for thrombin-mediated activation of protein C and thrombin-activatable fibrinolysis inhibitor (TAFI) and thereby helps coordinate coagulation, anticoagulation, fibrinolysis, and inflammation...
  49. ncbi Overall haemostatic potential can be used for estimation of thrombin-activatable fibrinolysis inhibitor-dependent fibrinolysis in vivo and for possible follow-up of recombinant factor VIIa treatment in patients with inhibitors to factor VIII
    J P Antovic
    Coagulation Research, Department of Surgical Sciences, Karolinska Institutet, Karolinska Hospital, Stockholm, Sweden
    Haemophilia 8:781-6. 2002
    ..and/or inhibitors to factor VIII/IX could enhance generation of thrombin-activatable fibrinolysis inhibitor (TAFI), a recently described link between coagulation and fibrinolysis...
  50. ncbi Thrombin activatable fibrinolysis inhibitor (TAFI) and markers of endothelial cell injury in dialyzed patients with diabetic nephropathy
    Jolanta Małyszko
    Department of Nephrology and Transplantology, Medical University, 15 540 Białystok Zurawia 14, Poland
    Thromb Haemost 91:480-6. 2004
    ..It has been postulated that TAFI-thrombin activatable fibrinolysis inhibitor, which couples two opposite systems: coagulation and fibrinolysis, may be involved in the ..
  51. ncbi Does recombinant factor VIIa, apart from overall hemostasis, regulate TAFI dependent fibrinolysis? In vitro analysis using overall hemostasis potential (OHP) assay
    Jovan P Antovic
    Coagulation Research, Department of Surgical Sciences, Karolinska Hospital, Stockholm, Sweden
    Thromb Haemost 90:620-7. 2003
    ..the effects of different concentrations of recombinant factor VIIa on overall hemostasis and on thrombin activatable fibrinolysis inhibitor (TAFI) dependent fibrinolysis in different factor deficient plasmas...
  52. ncbi Thrombin activatable fibrinolysis inhibitor and other hemostatic parameters in patients with essential arterial hypertension
    Jolanta Małyszko
    Department of Nephrology and Transplantology, Medical University, Białystok, Poland
    Pol Arch Med Wewn 118:36-41. 2008
    Hypertension is associated with hemostatic abnormalities and endothelial dysfunction. thrombin activatable fibrinolysis inhibitor (TAFI) is a glycoprotein linking coagulation and fibrinolysis. Objectives...
  53. ncbi Argatroban enhances fibrinolysis by differential inhibition of thrombin-mediated activation of thrombin activatable fibrinolysis inhibitor and factor XIII
    Vance G Nielsen
    Department of Anesthesiology, The University of Alabama at Birmingham, Birmingham, Alabama 35249 6810, USA
    Blood Coagul Fibrinolysis 19:793-800. 2008
    ..Direct thrombin inhibitors and heparin enhance fibrinolysis by inhibition of activation of thrombin activatable fibrinolysis inhibitor (TAFI); however, the role played by other thrombin-activated proteins [e.g...
  54. ncbi [Study of fibrinolysis inhibitors in 117 acute leukemia patients]
    Wen Wang
    Department of Hematology, Qilu Hospital of Shandong University, Jinan 250012, China
    Zhonghua Xue Ye Xue Za Zhi 29:183-6. 2008
    To explore the clinical significance of fibrinolysis inhibitors including thrombin activatable fibrinolysis inhibitor(TAFI), plasminogen activator inhibitor (PAI) and alpha2-plasmin inhibitor (alpha2-PI) in acute leukemia (AL).
  55. ncbi The role of thrombin activatable fibrinolysis inhibitor and factor XI in platelet-mediated fibrinolysis resistance: a thromboelastographic study in whole blood
    C Carrieri
    Department of Biomedical Sciences and Human Oncology, Section of General and Experimental Pathology, Aldo Moro University, Bari, Italy
    J Thromb Haemost 9:154-62. 2011
    ..The role of TAFI in platelet-mediated resistance to lysis is unclear...
  56. ncbi Thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and activity assay in patients with primary hypothyroidism
    Nilay Ermantas
    Internal Medicine, Medical Faculty, Trakya University, Edirne, Turkey
    Clin Appl Thromb Hemost 16:568-73. 2010
    ..It was recently shown that thrombin-activatable fibrinolysis inhibitor (TAFI) attenuates fibrinolysis and also fibrin-plasminogen interaction by the removal of lysine and arginine residues ..
  57. ncbi TAFI and PAI-1 levels in human sepsis
    Sacha Zeerleder
    Department of Hematology and Central Hematology Laboratory, Inselspital, Bern, Switzerland
    Thromb Res 118:205-12. 2006
    Plasminogen activator inhibitor type-1 (PAI-1) is considered to be the main inhibitor of fibrinolysis in sepsis. However, the contribution of TAFI to the inhibition of fibrinolysis in sepsis is currently unknown.
  58. ncbi Thrombin activatable fibrinolysis inhibitor (TAFI): relationship to hemostatic alteration in patients with beta-thalassemia
    Galila M Mokhtar
    Department of Pediatrics, Faculty of Medicine, Ain Shams University, Cairo, Egypt
    Pediatr Hematol Oncol 27:363-73. 2010
    Profound hemostatic changes have been observed among thalassemic patients. Thrombin activatable fibrinolysis inhibitor (TAFI) is a newly discovered protein that potentially attenuates fibrinolysis...
  59. ncbi TAFI deficiency in liver cirrhosis: relation with plasma fibrinolysis and survival
    Paolo Gresele
    Department of Internal Medicine, Division of Internal and Cardiovascular Medicine, University of Perugia, Via E dal Pozzo, 06126 Perugia, Italy
    Thromb Res 121:763-8. 2008
    b>TAFI (thrombin-activatable fibrinolysis inhibitor) is a potent anti-fibrinolytic and anti-inflammatory factor of liver origin...
  60. ncbi Dabigatran enhances clot susceptibility to fibrinolysis by mechanisms dependent on and independent of thrombin-activatable fibrinolysis inhibitor
    C T Ammollo
    Department of Biomedical Sciences and Human Oncology, Section of General and Experimental Pathology, University of Bari, Bari, Italy
    J Thromb Haemost 8:790-8. 2010
    ..counteracting the antifibrinolytic effects of thrombin, which include thrombin-activatable fibrinolysis inhibitor (TAFI) activation and clot structure enhancement...
  61. ncbi Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis
    T Lisman
    Thrombosis and Haemostasis Laboratory, Department of Haematology, University Medical Center, 3508 GA Utrecht, The Netherlands
    Gastroenterology 121:131-9. 2001
    ..In this study, the role of the recently discovered inhibitor of fibrinolysis, thrombin-activatable fibrinolysis inhibitor (TAFI) in cirrhosis was examined.
  62. ncbi Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation
    L O Mosnier
    Dept of Haematology, University Hospital, Utrecht, The Netherlands
    Thromb Haemost 80:829-35. 1998
    b>Thrombin Activatable Fibrinolysis Inhibitor (TAFI) is a recently identified fibrinolysis inhibitor in plasma, that when converted to an enzyme potently attenuates fibrinolysis...
  63. ncbi Admission fibrinolytic profile is associated with symptomatic hemorrhagic transformation in stroke patients treated with tissue plasminogen activator
    Marc Ribo
    Neurovascular Research Laboratory, Neurovascular Unit Hospital Vall d Hebron, Barcelona, Spain
    Stroke 35:2123-7. 2004
    ..We aim to determine the predictive value of pretreatment levels of fibrinolysis inhibitors (PAI-1, lipoprotein(a), TAFI, and homocysteine) on SICH.
  64. ncbi Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe hemophilia A
    Ton Lisman
    Thrombosis and Haemostasis Laboratory, Department of Haematology, Institute of Biomembranes, Van Creveldkliniek, University Medical Centre, Utrecht University, The Netherlands
    Blood 99:175-9. 2002
    ..not only a disorder of coagulation, but that hyperfibrinolysis due to a defective activation of thrombin activatable fibrinolysis inhibitor (TAFI) might also play a role...
  65. ncbi Activated thrombin-activatable fibrinolysis inhibitor attenuates spontaneous fibrinolysis of batroxobin-induced fibrin deposition in rat lungs
    Chengliang Wu
    Berlex Biosciences, Department of Pharmacology, P O Box 4099, 2600 Hilltop Drive, Richmond, A 94804 0099, USA
    Thromb Haemost 90:414-21. 2003
    Studies have shown that inhibition of TAFI by small peptides enhances pharmacological effects of tPA in animal models of thrombosis, suggesting that TAFI modulates the fibrinolytic system...
  66. ncbi Soluble CD40 ligand, plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor-1-antigen in normotensive type 2 diabetic subjects without diabetic complications. Effects of metformin and rosiglitazone
    Serkan Yener
    Division of Endocrinology and Metabolism, Department of Internal Medicine, Dokuz Eylul University School of Medicine, Izmir, Turkey
    Med Princ Pract 18:266-71. 2009
    ..To evaluate subclinical inflammation and fibrinolysis in low-risk type 2 diabetic subjects and to assess the efficacy of metformin and rosiglitazone in this group...
  67. ncbi Structural changes in carotid arteries and impairment of fibrinolysis in hemodialyzed and peritoneally dialyzed patients
    Jolanta Małyszko
    Department of Nephrology, Medical University, Białystok, Poland
    Med Sci Monit 15:CR644-9. 2009
    ..Thrombin-activatable fibrinolysis inhibitor (TAFI) is a recently discovered inhibitor of the fibrinolytic system...
  68. ncbi High functional levels of thrombin-activatable fibrinolysis inhibitor are associated with an increased risk of first ischemic stroke
    F W G Leebeek
    Department of Hematology, Erasmus University Medical Center, Rotterdam
    J Thromb Haemost 3:2211-8. 2005
    Several studies have suggested that thrombin-activatable fibrinolysis inhibitor (TAFI) levels are associated with the risk of arterial thrombosis, but results have been contradictory...
  69. ncbi The role of thrombin activatable fibrinolysis inhibitor in arterial thrombosis at a young age: the ATTAC study
    E L E de Bruijne
    Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands
    J Thromb Haemost 7:919-27. 2009
    b>Thrombin activatable fibrinolysis inhibitor (TAFI) attenuates fibrinolysis and may therefore contribute to the pathophysiology of arterial thrombosis...
  70. ncbi Absence of thrombin-activatable fibrinolysis inhibitor protects against sepsis-induced liver injury in mice
    Rosemarijn Renckens
    Laboratory of Experimental Internal Medicine, Amsterdam, The Netherlands
    J Immunol 175:6764-71. 2005
    Thrombin-activatable fibrinolysis inhibitor (TAFI), also known as carboxypeptidase R, has been implicated as an important negative regulator of the fibrinolytic system...
  71. ncbi Elevated thrombin activatable fibrinolysis inhibitor (TAFI) antigen levels in overt and subclinical hypothyroid patients were reduced by levothyroxine replacement
    Baris Akinci
    Dokuz Eylul University Medical School, Department of Internal Medicine, Division of Endocrinology and Metabolism, Izmir, Turkey
    Endocr J 54:45-52. 2007
    ..b>Thrombin activatable fibrinolysis inhibitor (TAFI) is an inhibitor of fibrinolysis, which has been recently isolated from human plasma...
  72. ncbi Thrombin activatable fibrinolysis inhibitor (TAFI) does not inhibit in vitro thrombolysis by pharmacological concentrations of t-PA
    M Colucci
    Department of Biomedical Sciences, University of Bari, Italy
    Thromb Haemost 85:661-6. 2001
    TAFI (thrombin activatable fibrinolysis inhibitor) is a plasma procarboxypeptidase that upon activation inhibits the fibrinolytic process by removing the C-terminal lysines from partially degraded fibrin...
  73. ncbi Secretion and antifibrinolytic function of thrombin-activatable fibrinolysis inhibitor from human platelets
    S L Schadinger
    Department of Biochemistry, Queen s University, Kingston, ON, Canada
    J Thromb Haemost 8:2523-9. 2010
    The thrombin-activatable fibrinolysis inhibitor (TAFI) is a zymogen first characterized in human plasma that is activated through proteolytic cleavage by thrombin, thrombin in complex with thrombomodulin, or plasmin...
  74. ncbi Thrombin-activatable fibrinolysis inhibitor antigen levels and cardiovascular risk factors
    I Juhan-Vague
    Laboratory of Hematology, Centre de Détection et de Prévention de l Athérosclérose, CHU Timone, Marseille, France
    Arterioscler Thromb Vasc Biol 20:2156-61. 2000
    Thrombin-activatable fibrinolysis inhibitor (TAFI) is a recently described fibrinolysis inhibitor that circulates in plasma as a procarboxypeptidase and is converted into an active form during coagulation...
  75. ncbi Reduced activity of TAFI (thrombin-activatable fibrinolysis inhibitor) in acute promyelocytic leukaemia
    J C Meijers
    The Department of Haematology, University Medical Centre, Utrecht, The Netherlands
    Br J Haematol 108:518-23. 2000
    ..Several processes are involved, such as disseminated intravascular coagulation and hyperfibrinolysis. Recently, TAFI (thrombin-activatable fibrinolysis inhibitor) was identified as a link between coagulation and fibrinolysis...
  76. ncbi Thrombin activatable fibrinolysis inhibitor and hemostatic changes in patients with type I diabetes mellitus with and without microvascular complications
    Jovan P Antovic
    Department of Surgical Sciences, Karolinska Institutet, Karolinska Institutet, Stockholm, Sweden Jovan
    Blood Coagul Fibrinolysis 14:551-6. 2003
    We investigated thrombin activatable fibrinolysis inhibitor (TAFI) and its influence on fibrinolysis by measuring pro-TAFI activity and total TAFI antigen in 38 patients with type I diabetes mellitus (18 with and 20 without microvascular ..
  77. ncbi The activation peptide of thrombin-activatable fibrinolysis inhibitor: a role in activity and stability of the enzyme?
    P F Marx
    Department of Vascular Medicine, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands
    J Thromb Haemost 7:445-52. 2009
    Thrombin-activatable fibrinolysis inhibitor (TAFI) is a 56-kDa procarboxypeptidase...
  78. ncbi Discovery of novel mechanisms and molecular targets for the inhibition of activated thrombin activatable fibrinolysis inhibitor
    K Hillmayer
    Laboratory for Pharmaceutical Biology, Faculty of Pharmaceutical Sciences, Katholieke Universiteit Leuven, Leuven
    J Thromb Haemost 6:1892-9. 2008
    b>Thrombin activatable fibrinolysis inhibitor (TAFI) is an important regulator of fibrinolysis and an attractive target to develop profibrinolytic drugs.
  79. ncbi Thrombin activatable fibrinolysis inhibitor (TAFI)--how does thrombin regulate fibrinolysis?
    Bonno N Bouma
    Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California 92037, USA
    Ann Med 38:378-88. 2006
    ..it not only forms the clot but it is also involved in stabilizing the clot by activating thrombin activatable fibrinolysis inhibitor (TAFI). Activated TAFI protects the fibrin clot against lysis...
  80. ncbi Comparative study of inhibitory antibody derivatives towards thrombin activatable fibrinolysis inhibitor
    Jan Develter
    Laboratory for Pharmaceutical Biology, Faculty of Pharmaceutical Sciences, Katholieke Universiteit Leuven, Belgium
    Thromb Haemost 102:69-75. 2009
    b>Thrombin activatable fibrinolysis inhibitor (TAFI) attenuates fibrinolysis and is considered as an attractive drug target...
  81. ncbi Curiouser and curiouser: recent advances in measurement of thrombin-activatable fibrinolysis inhibitor (TAFI) and in understanding its molecular genetics, gene regulation, and biological roles
    Michael B Boffa
    Department of Biochemistry, Queen s University, Kingston, Ontario, Canada K7L 3N6
    Clin Biochem 40:431-42. 2007
    The thrombin-activatable fibrinolysis inhibitor (TAFI) pathway defines a novel molecular connection between blood coagulation and both fibrinolysis and inflammation...
  82. ncbi Comparison of effects of different heparins on thrombin activatable fibrinolysis inhibitor in hemodialyzed patients
    Jolanta Małyszko
    Department of Nephrology and Transplantology, Medical University, Białystok, Poland
    Am J Nephrol 24:624-9. 2004
    b>Thrombin activatable fibrinolysis inhibitor (TAFI) is a regulator of endogenous fibrinolysis...
  83. ncbi Covalent linkage of recombinant hirudin to a novel ionic poly(carbonate) urethane polymer with protein binding sites: determination of surface antithrombin activity
    M D Phaneuf
    Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    Artif Organs 22:657-65. 1998
    ..This BSA-SMCC complex was then covalently linked to the carboxylated polyurethane (cPU) surface via the crosslinker EDU (cPU-BSA-SMCC)...
  84. ncbi Calcium antagonistic and antiarrhythmic actions of CPU-23, a substituted tetrahydroisoquinoline
    H Dong
    Department of Physiology, Faculty of Medicine, University of Hong Kong
    Br J Pharmacol 109:113-9. 1993
    1. The effects of CPU-23 (1-(1-[(6-methoxyl)-naphth-2-yl])-propyl-2-(1-piperidine)-acetyl-6 ,7- dimethyoxy-1,2,3,4-tetra-hydroisoquinoline) were studied on mechanical and electrical activities, and intracellular free calcium ([Ca2+]i) of ..
  85. ncbi Sensitized increase of period gene expression in the mouse caudate/putamen caused by repeated injection of methamphetamine
    T Nikaido
    Department of Pharmacology and Brain Science, School of Human Sciences, Waseda University, Tokorozawa, Saitama, Japan
    Mol Pharmacol 59:894-900. 2001
    ..Although the caudate/putamen (CPu) expresses mPer1 and/or mPer2 mRNA, the function of these genes in this nucleus has not yet been elucidated...
  86. ncbi A comparison between automatically generated linear and parabolic tetrahedra when used to mesh a human femur
    K Polgar
    Oxford Orthopaedic Engineering Centre, University of Oxford, Nuffield Orthopaedic Centre, Windmill Road, Headington, Oxford OX3 7LD, UK
    Proc Inst Mech Eng H 215:85-94. 2001
    ..were compared with four-node linear tetrahedron elements (T4) on the basis of accuracy and central processing unit (CPU) time...
  87. ncbi Increases in cytoplasmic dopamine compromise the normal resistance of the nucleus accumbens to methamphetamine neurotoxicity
    David M Thomas
    Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA
    J Neurochem 109:1745-55. 2009
    ..The brain structure most affected by METH is the caudate-putamen (CPu) where long-term DA depletion and microglial activation are most evident...
  88. ncbi Comparison of two immunochemical assays for measuring thrombin-activatable fibrinolysis inhibitor concentration with a functional assay in patients with acute coronary syndrome
    Mika Skeppholm
    Karolinska Institutet, Department of Clinical Sciences, Danderyd Hospital, Division of Cardiology, SE 182 88 Stockholm, Sweden
    Thromb Res 121:175-81. 2007
    b>TAFI was measured as relative activity concentration (Pefakit) and antigen concentration (Haemochrom and Asserachrom) both acutely and during convalescence in patients suffering from acute coronary syndrome, and in a group of healthy ..
  89. ncbi Protective role of thrombin activatable fibrinolysis inhibitor in obstructive nephropathy-associated tubulointerstitial fibrosis
    N E Bruno
    Department of Diabetes and Endocrinology, Mie University Graduate School of Medicine, Tsu City, Mie, Japan
    J Thromb Haemost 6:139-46. 2008
    Thrombin-activatable fibrinolysis inhibitor (TAFI) has been reported to affect wound healing and fibrotic processes, but its role in renal tubulointerstitial fibrosis remains unknown.
  90. ncbi Clot life span model analysis of clot growth and fibrinolysis in normal subjects: role of thrombin activatable fibrinolysis inhibitor
    Vance G Nielsen
    Department of Anesthesiology, The University of Alabama at Birmingham, Birmingham, Alabama 35249 6810, USA
    Blood Coagul Fibrinolysis 19:283-7. 2008
    ..This study proposed to kinetically define fibrinolytic vulnerability and the contribution of thrombin activatable fibrinolysis inhibitor to fibrinolytic defenses in normal subjects...
  91. ncbi Carboxypeptidase U (TAFIa): a new drug target for fibrinolytic therapy?
    J L Willemse
    Laboratory of Medical Biochemistry, University of Antwerp, Antwerp, Belgium
    J Thromb Haemost 7:1962-71. 2009
    ..The development of carboxypeptidase U (CPU) inhibitors as profibrinolytic agents is an attractive concept and possibilities for rational drug ..
  92. ncbi Soluble thrombomodulin partially corrects the premature lysis defect in FVIII-deficient plasma by stimulating the activation of thrombin activatable fibrinolysis inhibitor
    J H Foley
    Department of Biochemistry, Queen s University, Kingston, ON, Canada
    J Thromb Haemost 7:453-9. 2009
    ..in plasmas deficient in components of the intrinsic pathway, due to a failure to activate thrombin activatable fibrinolysis inhibitor (TAFI)...
  93. ncbi Immune complex-mediated glomerulonephritis is ameliorated by thrombin-activatable fibrinolysis inhibitor deficiency
    Nelson E Bruno
    Department of Immunology, Mie University Graduate School of Medicine, Edobashi 2 174, Tsu City, 514 8507 Mie, Japan
    Thromb Haemost 100:90-100. 2008
    ..Thrombin-activatable fibrinolysis inhibitor (TAFI) is a potent inhibitor of plasmin generation...
  94. ncbi Increased plasma thrombin-activatable fibrinolysis inhibitor levels in young obese women with polycystic ovary syndrome
    Ertan Adali
    Department of Obstetrics and Gynecology, Yuzuncu Yil University, Van, Turkey
    Fertil Steril 94:666-72. 2010
    ....
  95. ncbi Antithrombotic effects due to pharmacological modulation of thrombin-activatable fibrinolysis inhibitor in rats
    Hitesh Soni
    Zydus Research Centre, Ahmedabad, India
    Pharmacology 82:304-9. 2008
    Thrombin-activatable fibrinolysis inhibitor (TAFI) is a basic carboxypeptidase zymogen that can be activated by thrombin...
  96. ncbi Development of sandwich-type ELISAs for the quantification of rat and murine thrombin activatable fibrinolysis inhibitor in plasma
    K Hillmayer
    Laboratory for Pharmaceutical Biology, Faculty of Pharmaceutical Sciences, Katholieke Universiteit Leuven, Leuven, Belgium
    J Thromb Haemost 6:132-8. 2008
    Altered plasma levels of thrombin activatable fibrinolysis inhibitor (TAFI) are associated with a large number of pathologies...
  97. ncbi Symptoms of problematic cellular phone use, functional impairment and its association with depression among adolescents in Southern Taiwan
    Cheng Fang Yen
    Department of Psychiatry, Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
    J Adolesc 32:863-73. 2009
    The aims of this study were: (1) to examine the prevalence of symptoms of problematic cellular phone use (CPU); (2) to examine the associations between the symptoms of problematic CPU, functional impairment caused by CPU and the ..
  98. ncbi Procarboxypeptidase U (TAFI) and the Thr325Ile proCPU polymorphism in patients with hereditary mucocutaneous hemorrhages
    Valeria Matus
    Department of Haematology Oncology, School of Medicine, Pontificia Universidad Catolica de Chile, Santiago, Chile
    Clin Chim Acta 401:158-61. 2009
    ..Theoretically, decreased plasma procarboxypeptidase U (proCPU) levels or lower carboxypeptidase U (CPU) stability would result in higher fibrinolytic activity and bleeding tendency.
  99. ncbi The bone tissue responses to prehydrated and collagenated cortico-cancellous porcine bone grafts: a study in rabbit maxillary defects
    Ulf Nannmark
    Institute of Biomedicine, Sahlgrenska Academy, Goteborg University, Goteborg, Sweden
    Clin Implant Dent Relat Res 10:264-70. 2008
    ..Adding collagen gel to prehydrated and collagenated porcine bone (PCPB) particles results in a sticky and moldable material which facilitates clinical handling...
  100. ncbi Thrombin-activatable fibrinolysis inhibitor deficiency attenuates bleomycin-induced lung fibrosis
    Hajime Fujimoto
    Institute of Clinical Medicine and Biomedical Sciences, Department of Pulmonary and Critical Care Medicine, Mie University Graduate School of Medicine, Edobashi 2 174, Tsu City, Mie 514 8507, Japan
    Am J Pathol 168:1086-96. 2006
    ..Thrombin-activatable fibrinolysis inhibitor (TAFI) is a strong suppressor of fibrinolysis, but its role in lung fibrosis is unknown...
  101. ncbi Evidence for natural horizontal transfer of the pcpB gene in the evolution of polychlorophenol-degrading sphingomonads
    Marja A Tiirola
    Department of Biological and Environmental Science, FIN 400014 University of Jyväskylä, Finland
    Appl Environ Microbiol 68:4495-501. 2002
    The chlorophenol degradation pathway in Sphingobium chlorophenolicum is initiated by the pcpB gene product, pentachlorophenol-4-monooxygenase...

Research Grants67

  1. Factor Xl in Vascular Thrombosis
    David Gailani; Fiscal Year: 2010
    ..to fibrin formation, fXIa promotes clot resistance to fibrinolysis in a process involving the proteinase TAFI. Several lines of evidence indicate fXIa contributes to pathologic coagulation...
  2. Factor Xl in Vascular Thrombosis
    David Gailani; Fiscal Year: 2007
    ..to fibrin formation, fXIa promotes clot resistance to fibrinolysis in a process involving the proteinase TAFI. Several lines of evidence indicate fXIa contributes to pathologic coagulation...
  3. Carboxypeptidases in Thrombosis and Inflammation
    Laszlo Bajzar; Fiscal Year: 2007
    ..The two CP, activated TAFI (TAFla) and carboxypeptidase N (CPN) both remove C-terminal lysine and arginine residues from protein substrates...
  4. STRUCTURAL STUDIES OF BLOOD CLOTTING PROTEINS
    JOHN WEISEL; Fiscal Year: 2004
    ..enzyme/activator and the mode of its introduction, and the presence of other proteins, such as Lp(a), PAI-1, and TAFI. One of the principal approaches will be to follow digestion in real time using confocal microscopy in both ..
  5. CLASSICAL AND ALTERNATIVE PATHWAYS OF FIBRINOLYSIS
    Edward Plow; Fiscal Year: 2005
    ..are apo(a), which is composed of multiple kringles, including ones with LBS activity, and plasma carboxypeptidaseB, TAFI, which removes the C-terminal lysines from degrading fibrin and cell surfaces...
  6. CLASSICAL AND ALTERNATIVE PATHWAYS OF FIBRINOLYSIS
    EDWARD FRANKLIN PLOW; Fiscal Year: 2010
    ..In addition, modulators of the LBS of plasminogen, apoprotein(a) and TAFI, occur naturally and their influence on plasminogen-dependent inflammatory responses of plasminogen will be ..
  7. CLASSICAL AND ALTERNATIVE PATHWAYS OF FIBRINOLYSIS
    Edward Plow; Fiscal Year: 2007
    ..In addition, modulators of the LBS of plasminogen, apoprotein(a) and TAFI, occur naturally and their influence on plasminogen-dependent inflammatory responses of plasminogen will be ..
  8. Clotting genetic variant, hormones and venous thrombosis
    Nicholas Smith; Fiscal Year: 2007
    ..protein C, endothelial protein C receptor, protein S, antithrombin III, tissue activatable fibrinolysis inhibitor (TAFI), tissue plasminogen activator (TPA), and factors VIII, IX, X, and XlII A and B...
  9. EPCR, TAFI as Regulators of PMN/Endothelial Interaction
    Florea Lupu; Fiscal Year: 2009
    ..studies focus on the role of endothelial protein C receptor (EPCR) and thrombin activatable fibrinolytic inhibitor (TAFI) as regulators of the neutrophil/endothelial interaction induced by E. coli...
  10. MECHANISMS OF MICROVASULAR THROMBOSIS IN BABOONS
    Fletcher Taylor; Fiscal Year: 2002
    ..Coli) models of DIC. TAFI, the newest member of fibrinolytic inhibitors which are connected to the protein C network, also is unique in that, ..
  11. Genetic Analysis of Idiopathic Thrombosis
    Laura A Almasy; Fiscal Year: 2010
    ..XII linkage on chromosome 10, by assessing association with a gene-centric panel of SNPs;2) to determine whether CPB2 is the previously detected QTL on chromosome 13 influencing levels of thrombin-activatable fibrinolysis inhibitor (..
  12. Genetic Analysis of Idiopathic Thrombosis
    Laura Almasy; Fiscal Year: 2009
    ..XII linkage on chromosome 10, by assessing association with a gene-centric panel of SNPs; 2) to determine whether CPB2 is the previously detected QTL on chromosome 13 influencing levels of thrombin-activatable fibrinolysis inhibitor (..
  13. Genetic Analysis of Idiopathic Thrombosis
    Laura Almasy; Fiscal Year: 2007
    ..XII linkage on chromosome 10, by assessing association with a gene-centric panel of SNPs; 2) to determine whether CPB2 is the previously detected QTL on chromosome 13 influencing levels of thrombin-activatable fibrinolysis inhibitor (..
  14. EPIDEMIOLOGY OF VENOUS THROMBOSIS AND PULMONARY EMBOLISM
    Aaron Folsom; Fiscal Year: 2006
    ..measure analytes found to be important in LITE already (factor V Leiden, prothrombin G20210A variant, D-dimer, and TAFI), to serve as covariates in combined analyses. 2...
  15. EPIDEMIOLOGY OF VENOUS THROMBOSIS AND PULMONARY EMBOLISM
    Aaron Folsom; Fiscal Year: 2003
    ..measure analytes found to be important in LITE already (factor V Leiden, prothrombin G20210A variant, D-dimer, and TAFI), to serve as covariates in combined analyses. 2...
  16. Obesity, Inflammation and Thrombosis: LOOK AHEAD
    Christie Ballantyne; Fiscal Year: 2009
    ..adiponectin isoforms) adipocytokines and parameters of impaired coagulant balance (PAI-1, fibrinogen, D-dimer, TAFI) in 50% of patients enrolled in the Look AHEAD trial and how this relationship is influenced by dietary intake, ..
  17. Obesity, Inflammation and Thrombosis: LOOK AHEAD
    Christie M Ballantyne; Fiscal Year: 2010
    ..adiponectin isoforms) adipocytokines and parameters of impaired coagulant balance (PAI-1, fibrinogen, D-dimer, TAFI) in 50% of patients enrolled in the Look AHEAD trial and how this relationship is influenced by dietary intake, ..
  18. Obesity, Inflammation and Thrombosis: LOOK AHEAD
    Christie Ballantyne; Fiscal Year: 2007
    ..adiponectin isoforms) adipocytokines and parameters of impaired coagulant balance (PAI-1, fibrinogen, D-dimer, TAFI) in 50% of patients enrolled in the Look AHEAD trial and how this relationship is influenced by dietary intake, ..
  19. FUNCTIONAL MAPPING AND PROTEIN ENGINEERING OF THROMBIN
    Lawrence Leung; Fiscal Year: 2007
    ..b>TAFI is a latent plasma carboxypeptidase, which is activated by the thrombin-thrombomodulin (TM) complex on endothelial ..
  20. Cross-talk Between Coagulation, Inflammation, and Immunity
    Lawrence L Leung; Fiscal Year: 2010
    Based on studies with the pCPB KO mice, we have obtained compelling data to support our general hypothesis that thrombin-activatable carboxypeptidase B (CPB or TAFIa) plays a broad anti-inflammatory role in vivo;the targets for CPB ..
  21. The Role of Carboxypeptidase B and its Substrates in Rheumatoid Arthritis
    William H Robinson; Fiscal Year: 2010
    ..Genetic association studies using tag single nuclear polymorphisms (SNPs) representing the CPB2 gene showed that the minor allele SNP rs1409433 was associated with a reduced RA disease susceptibility...
  22. Development of a PEM-PET-CT Breast Imaging and Biopsy Device
    RAYMOND RAYLMAN; Fiscal Year: 2009
    ..1mm). Image reconstruction is performed with a 3D-OSEM algorithm optimized to run on an eight CPU computer system, significantly reducing image reconstruction times...
  23. Development of a PEM-PET-CT Breast Imaging and Biopsy Device
    RAYMOND ROBERT RAYLMAN; Fiscal Year: 2010
    ..1mm). Image reconstruction is performed with a 3D-OSEM algorithm optimized to run on an eight CPU computer system, significantly reducing image reconstruction times...
  24. Comprehensive Molecular Diagnosis for Food and Waterborne Enteropathogens
    Eric Houpt; Fiscal Year: 2007
    ..extraction procedures amidst the complex mixture of stool to increase sensitivity towards the goal of culture (100 CPU bacteria/g)...
  25. Basal ganglia modulation of trigeminal intralaminar nuclei thalamic activity
    Eric Chudler; Fiscal Year: 2007
    ..The first specific aim is to analyze the connectivity between the caudate- putamen (CPu) and intralaminar nuclei of the thalamus by testing the effects of electrical CPu stimulation on the responsiveness ..
  26. EM-TRANSMITTER INTERACTIONS OF STRIATAL OPIOID NEURONS
    VIRGINIA PICKEL; Fiscal Year: 2007
    Glutamatergic cortical inputs to the nucleus accumbens (NAc) and caudate-putamen (CPu) control motivated behaviors directly influenced by reward and by addictive drugs that can produce long-term changes in synaptic efficacy...